A gift to the UCSF Department of Surgery can help physicians and scientist find treatments and cures for serious liver diseases such as hepatitis B & C, and liver cancer.
| Academic Office Division of Gastroenterology 513 Parnassus Avenue, Room S-357 San Francisco, CA 94143-0358 Phone: (415) 476-2777 415-476-0659 marion.peters@ucsf.edu | Liver Transplant Program 400 Parnassus Ave., Sixth Floor San Francisco, CA 94143 Phone: (415) 353-1888 Gastroenterology and Liver Faculty Practice 350 Parnassus Ave., Suite 410 San Francisco, CA 94143 Phone: (415) 353-2318 |
Dr. Marion Peters is a Professor of Medicine and holds the John V. Carbone, M.D., Endowed Chair in Medicine. She is also Chief of Hepatology Research. Dr. Peters is especially interested in the immunology of chronic liver diseases, particularly viral and autoimmune hepatitis. Her research activities include studies of transgenic mouse models of liver specific T cell responses, HIV and HCV coinfection, and alcohol and HCV infection.
Dr. Peters graduated from Melbourne University Medical School, Australia in 1972. She trained in gastroenterology, hepatology and immunology at St. Vincent's Hospital, Melbourne, University of Southern California and National Institutes of Health. She was Chief of Hepatology and medical director of Liver Transplantation at Washington University School of Medicine from 1985 to 1998.
My major interest is in viral hepatitis and the role of the host immune response. My work focuses on interactions among alcohol use, cannabis use and HIV co-infection on fibrotic outcomes of HCV infection. We are currently evaluating the predictors of progression of liver disease in HIV and HCV coinfected women within the Women's Interagency HIV Study (WIHS): the role of alcohol, cannabis, HIV status and control as well as reproductive aging on the severity and rate of progression of liver disease.
We are also studying adherence to antiretroviral therapy in HIV/HCV co-infected women and on HCV-specific and innate immune responses in persons co-infected with HCV and HIV. I work within the AIDS Clinical Trial Group to develop clinical trials in viral hepatitis and HIV and within the Women's Interagency HIV Study (WIHS) to examine predictors of liver-related morbidity and mortality in a cohort of women with HIV/HCV infection.